单核细胞趋化蛋白1及其受体CCR2与冠心病关系的研究进展

摘要

冠状动脉粥样硬化性心脏病是一种慢性炎症性疾病,炎性反应在动脉粥样硬化(AS)发生、发展及其并发症的产生过程中起着重要作用,而趋化因子及受体在炎性反应中起关键作用.其中单核细胞趋化蛋白1(MCP-1)被认为是AS发生早期的关键因素,它与其特异性受体CC类趋化因子受体2(CCR2)结合后,趋化并激活单核/巨噬细胞,促进炎性反应的发生,从而产生生物学效应.现就MCP-1及CCR2在冠心病炎性反应过程中的作用,以及治疗冠心病的可行方案予以综述.%Coronary atherosclerotic heart disease ( CAHD )is a chronic inflammatory disease, inflammation has an important effect in the atherosclerosis( AS )occurrence and development and the process of its complications,chemotactic factors and receptors play a key role in the infiammation.Among them, monocyte chemoattractant protein-l( MCP-1 )is considered as a critical factor in the early formation of atherosclerotic plaques,which can make monocyte/macrophages chemotactic and active, promote inflammation, result in the occurrence of biological effects after being combined with its specific receptors CC chemokine receptor 2 ( CCR2 ).Here is to review the roles of MCP-1 and CCR2 in the inflammatory processes of coronary heart disease, providing a feasible solution for coronary heart disease.